Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 75%
filed 2026-06-15
EX-99.1
Ecopetrol announces a final collective bargaining agreement with the Oil Workers Union (USO) and 66 other labor unions, effective January 1, 2026, following over 990 negotiation sessions. The agreement includes improvements in working conditions, health and education benefits, diversity initiatives, and social investment. This is a material operational and labor-relations event affecting a major integrated energy company with 19,000+ employees, as it resolves a significant labor negotiation and establishes terms for a six-year period, but does not fit the specific categories of workforce reduction, exec compensation, or governance matters.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
EX-99.1
Cuprina announced receipt of U.S. FDA 510(k) clearance for MEDIFLY Maggots, a medical-grade Lucilia cuprina larvae product for maggot debridement therapy. This is a significant regulatory milestone and product approval that enables commercial launch in the U.S. market. While not a discrete M&A, financing, or governance event, this regulatory clearance is a material operational and strategic achievement that would affect a reasonable investor's assessment of the company's product portfolio and market opportunities, particularly as it positions Cuprina as the only company holding FDA clearance for both maggot species used in MDT.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
EX-99.1
Dr. Reddy's announces the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States on June 13, 2026. This is a material product launch in the oncology segment with 180-day generic drug exclusivity, targeting a market with approximately $253.8 million in annual sales for the branded equivalent. The disclosure is a strategic operational milestone—a new product commercialization—rather than a discrete financial event (earnings, debt, M&A) or governance matter, making it operational_other.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
This 6-K discloses FDA approval of Truqap (capivasertib) in combination with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer, based on positive Phase III CAPItello-281 trial results showing a 19% reduction in risk of disease progression or death. This is a material regulatory milestone and product approval event that expands AstraZeneca's oncology portfolio into a second tumor type, representing a significant operational and commercial development rather than a discrete financial, governance, or legal event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-15
EX-99.2
This press release announces FDA approval of Obagi® saypha® ChIQ™, a new injectable hyaluronic acid gel product for the Obagi Medical brand (owned by Waldencast). The approval expands Obagi's injectable portfolio and strengthens its position in the dermal filler market. This is a material operational/product milestone—a regulatory approval that materially expands the company's addressable market in the fast-growing U.S. dermal filler category and advances its strategy to establish Obagi as a comprehensive leader in medical aesthetics. While not a discrete M&A, litigation, or financial event, the approval of a new product with significant market potential is material to investors assessing the company's growth trajectory and competitive positioning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
EX-99.1
DHT Holdings announced entry into an agreement with Hanwha Ocean for construction of a new VLCC vessel scheduled for delivery in August 2028, representing a material capital deployment and fleet expansion decision financed through cash flow, liquidity, and projected mortgage debt.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-12
EX-99.1
Austin Gold has filed a National Instrument 43-101 technical report on its Stockade Mountain Project documenting exploration activities, drilling results (including significant gold grades of 8.19 g/t and 9.32 g/t), and identifying new untested drill targets based on geophysical surveys. This material operational disclosure advances the company's core business objective of making district-scale gold discoveries and demonstrates progress on its primary asset.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-12
The 6-K discloses positive Phase 2 clinical trial results for TransCon PTH (palopegteriparatide) in hypoparathyroidism, announced June 11, 2026. The five-year PaTH Forward Trial data demonstrates sustained efficacy and safety with high responder rates (82%), maintained kidney function improvements, and quality-of-life benefits. This is a material clinical milestone for a biopharmaceutical company's lead program, but it is not a discrete event type in the taxonomy (not earnings, M&A, litigation, or other named categories). It is clearly operational—a significant product development and regulatory milestone—making `operational_other` the best fit.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
EX-99.2
The European Commission approved Sarclisa (isatuximab) subcutaneous formulation administered via an on-body injector for multiple myeloma treatment. This regulatory approval expands the commercial availability and delivery method of the existing marketed drug, representing a material operational and commercial development for Sanofi's oncology portfolio.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-12
EX-99.3
Sanofi terminated the MOBILIZE phase 3 clinical trial of riliprubart in CIDP patients following an interim analysis showing insufficient efficacy. The failure of the phase 3 study represents a material setback to the company's pipeline and R&D direction, affecting investor assessment of future revenue potential.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
EX-99.1
Hydro One announced filing a leave-to-construct application with the Ontario Energy Board for the Durham Kawartha Power Line, a ~$430 million transmission infrastructure investment project expected to be in service in 2029. This is a material operational and strategic business event—a major capital project milestone involving regulatory approval—that does not fit a specific named category. The scale ($430M investment), strategic importance to grid reliability and growth support, and First Nations partnership equity component make this material to investors assessing the company's capital deployment and operational strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
EX-99.1
Hydro One announced filing a leave-to-construct application with the Ontario Energy Board for the Durham Kawartha Power Line, a ~$430 million transmission infrastructure investment project expected to be in service in 2029. This is a material operational and strategic business event—a major capital project announcement involving regulatory approval—that does not fit a specific named category. The scale ($430M investment), strategic importance (grid reliability and growth support), and First Nations partnership model make this material to investors assessing the company's capital deployment and operational strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
EX-99.1
Park Ha Biological announced a comprehensive strategic partnership with Star Plus Action (subsidiary of Star Plus Legend Holdings) to build an AI-powered skincare and health ecosystem. The disclosure describes joint development of AI-powered products (AI Nutritionist, AI store managers, AI skincare specialists), resource integration across healthcare, skincare, IP management, and AI technology, and plans for full-chain intelligent service deployment. This is a material operational and strategic business event—a significant partnership and business model expansion—that does not fit the specific categories of M&A activity (no acquisition/merger/change of control), debt issuance, or other named types. It represents a transformative strategic collaboration affecting the company's business direction and competitive positioning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-12
GSK announced that momelotinib received Orphan Drug Designations (ODD) from the FDA and EMA for VEXAS syndrome treatment, with a planned phase II/III ATLAS trial underway. This is a material regulatory milestone for a rare disease indication that would affect investor assessment of the company's pipeline and development strategy, but it does not fit the specific event categories (not an earnings release, M&A activity, executive change, debt issuance, or other named types). The ODD designation and trial advancement represent a significant operational/strategic development in the drug's regulatory pathway.
View raw filing on EDGAR →